| INTRODUCTION
GC is one of the most common malignancies with the second highest morbidity and mortality rate. 1 Early diagnosis is difficult because it is often asymptomatic or only moderate nonspecific symptoms are manifested at the early stage. Consequently, most patients suffer from the advanced stages of GC upon first diagnosis. [2] [3] [4] Treatments for advanced GC are mainly focused on surgical combined with adjuvant chemotherapy. However, surgical removal could not cure for a number of patients with late-stage GC. Therefore, to maximum surgery outcome and improve prognosis, neoadjuvant chemotherapy has been adopted widely resulting in increased tumorectomy succeed and enhanced treatment outcomes. [5] [6] [7] [8] However, the effectiveness of current chemotherapies in patients with GC remains unpredictable including neoadjuvant chemotherapy. If biomarkers are available for predicting outcomes and adverse effects of neoadjuvant chemotherapy, the treatment ratio for advanced GC may be able to improve. Therefore, new biomarker detection is of significance for clinical practice.
MicroRNAs are single-stranded RNA molecules with [18] [19] [20] [21] [22] [23] [24] [25] nucleotides in length, having functions in regulating target posttranscriptional genes. [9] [10] [11] Recent findings show that microRNAs play a pivotal role in GC progress, and researches have revealed that in GC tissues or cells, miR-145, miR-185, miR-381, and miR-195 appear aberrant expression and also are involved in regulating GC cell proliferation, apoptosis, and metastasis. [12] [13] [14] [15] However, little researches have been conducted to explore the expression of these microRNAs in peripheral blood of patients with GC and the association between expression of these microRNAs and neoadjuvant chemotherapy. This study aims to test the expression of miR-145, miR-381, miR-185, and miR-195 in peripheral blood of patients with GC and explore the possibility of their expression to be predictive markers for the outcome of neoadjuvant chemotherapy. A total of 120 patients with GC receiving SOX regimen as neoadjuvant chemotherapy were recruited, and the expression of miR-145, miR-381, miR-185, and miR-195 in their peripheral blood was investigated. In addition, these markers in predicting outcomes of neoadjuvant chemotherapy were further analyzed, and the results of this study may provide certain evidence to improve the GC treatment. 
| MATERIALS AND METHODS

| Population study
| Sample collection
A total of 4 mL of fasting blood sample were collected each time per person for microRNA detection. Fasting venous blood was collected twice in participates of the case group with the first sample collected a day before chemotherapy and the second gathered 1 day before surgery. The blood samples were obtained from the control group only once. All of the blood samples were collected in anticoagulation tubes and stayed still for 30 minutes. After that, these samples were centrifuged for serum separation, and stored at −80°C.
| Quantitative PCR detection of miR-145, miR-185, miR-381, and miR-195 expression in serum
Total RNA was extracted from serum of blood samples, strictly following the manufacturer's instruction. All reagent kits targeting each microRNA were from GeneCopia, and U6 snRNA was utilized as internal reference 
| Statistical analysis
Research data statistically analyzed using Statistical Product and Service Solutions (SPSS) 18.0. MicroRNA's relative expressive level was expressed as mean ± SD (x ± s). Comparison of MicroRNA expression levels between case and control group was examined by independent samples t tests. In the case group, expression levels of microRNA before and after treatments were compared using paired sample t tests. One-way analysis of variance (ANOVA) was applied to examine differences in microRNA expression level between patients with different outcomes of treatment. Differences between any pair of means were detected using SNK test. Adverse events in relation to microRNA expression level were compared using group comparison t tests. Receiver operating characteristic (ROC) curve was applied for evaluation of the predictive value of microRNA expression level in diagnosis, outcome evaluation, and adverse effect prediction in gastric carcinoma. P < .05 was considered statistically significant. 
| RESULTS
| Efficacy of neoadjuvant chemotherapy
| Alteration in miR-145, miR-185, miR-381, and miR-195 serum expression levels of patients with GC after neoadjuvant chemotherapy
In the chemotherapy recipients, miR-145, and miR-185 levels elevated drastically, whereas changes in miR-381, and miR-195 levels before and after neoadjuvant chemotherapy were considered no statistical significance (P > .05) ( Table 2) . T A B L E 1 Comparison of miR-145, miR-185, miR-381, and miR-195 expression between patients with GC before chemotherapy and the control group in each group (P < .05), but its level was not related to the outcome of neoadjuvant chemotherapy. miR-195 expression had no difference statistically in these groups (P > .05) ( Table 3 ).
| Association of serum levels of miR-145, miR-185, miR-381, and miR-195 before chemotherapy with their related adverse events in GC
Results indicate that patients with bone marrow suppression had lower miR-145 expression compared with those without (P < .05), but this tendency of expression was absent in other microRNAs. The results also detected the expressions of these 4 microRNAs were not related to peripheral neuropathy (P > .05) ( Table 4 ).
| DISCUSSION
In China, GC is one of the most common cancers and responds to a high mortality rate. 16 Despite numerous researches on it, there is still no highly effective treatment for GC. 17 Current treatments for GC are a combination of surgical, chemotherapy, radiation, target therapy and biotherapy, in which, surgery is particularly adopted as a main treatment. 18 However, surgery alone is not effective to treat patients with GC in advance stage. Many patients in advanced stage of CG suffered cancer recurrence soon after surgery. Therefore, neoadjuvant chemotherapy is recently widely utilized prior surgery to achieve the optimal outcome of CG treatment. 7, 19, 20 Neoadjuvant chemotherapy is a treatment applying on GC patients with advanced stage, and their may be a novel therapeutic option for the treatment of patients with GC. 30 However, little agreement is reached in relation to how these microRNAs express in the peripheral blood in patients with GC. This study reports that the expression of miR-145, miR-185, and miR-381 appeared altered in the peripheral blood in patients with GC. These three microRNAs can be potential novel marker s of GC examination, although more researches about their expression in the peripheral blood are still needed.
To understand the values and feasibility of these 4 microRNAs as biomarkers for neoadjuvant chemotherapy, this study examined the differences in the microRNA expression in the peripheral blood in neoadjuvant chemotherapy recipients before and after treatment.
miR-145 and miR-185 were found increased levels in patients with GC after treatment. This result suggests that chemotherapy could influence miR-145 and miR185 levels. Furthermore, our study compared patients in PR, SD and PD groups in terms of therapeutic outcomes and microRNA expression in the peripheral blood. The result shows decreased expression of miR-145 and miR-185 in PR, SD, PD groups in a descending order. Accordingly, we conclude that a considerable decrease in miR-145 and miR185 in the peripheral blood may suggest unsatisfactory outcomes of SOX neoadjuvant chemotherapy. Another therapeutic option might be better. However, this conclusion requires further research conducted in multiple centers with a larger scale of samples to confirm.
We further analyzed the association of the 4 microRNAs with major adverse events in chemotherapy. Results show that the miR-145 expression was lower in patients with bone marrow suppression than those with none, while none of these mircroRNAs was correlated with gastrointestinal adverse reactions and peripheral nerve injuries.
MiR-145 is suggested to be utilized to predict myelotoxicity before SOX neoadjuvant chemotherapy.
In sum, this study finds aberrant expression in advanced patients with GC their peripheral blood. Some microRNAs can assist in predict- 
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